Receive The Newest Study Notifications

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that the last patient has been included in the Phase 2 trial evaluating TG4010 in combination with Opdivo® (nivolumab) and...

Isabelle Richard's team, a CNRS researcher in an Inserm unit at Genethon, the AFM-Telethon laboratory, has demonstrated the efficacy of gene therapy and determined the effective dose for treating a rare muscle disease, gamma-sarcoglycanopathy, in mouse models of the...

by Deborah Mann Lake, University of Texas Health Science Center at Houston writes:  Something as simple as a phone call could be a way to alert health care providers and caregivers that an elderly person suffering from dementia may be spiraling down to dangerous...

Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases Rejenevie™ Therapeutics announced the commencement of the company's Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune...

28th May 2019. In acknowledgement of International Clinical Trials Day, MSD wants to say thank you to the 500 MSD clinical trial patients around the country.1 MSD New Zealand Director, Paul Smith says, “MSD is one of the few pharmaceutical companies undertaking...

ETHERAL Europe Reached 100 Patients Randomized Last Week MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / May 29, 2019 / Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in...

As the leader in Advanced Diagnostics, including Next Generation Sequencing (NGS), Quest joins a select group of commercial and academic laboratories to meet the rigorous requirements for participation in this clinical trial Both the Quest Med Fusion 50SEQ cancer...

First major double-blind trial of cannabidiol (CBD) remedies for dogs Therabis "Mobility" to be studied for its effectiveness in treating osteoarthritic pain Researchers seeking treatment options for the joint mobility issues affecting more than 50% of older dogs Led...

Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by the Group,...

Ansun Biopharma, Inc., today announced that the first patient has been enrolled in its Phase 3 clinical trial evaluating the efficacy and safety of DAS181 for the treatment of hospitalized, immunocompromised patients with lower respiratory tract parainfluenza virus...

A bioengineered human acellular vessel may help veterans with kidney failure The VA Pittsburgh Healthcare System (VAPHS) in collaboration with the Veterans Research Foundation of Pittsburgh (VRFP) is participating in the first-of-its-kind clinical trial that will help...

. Make recommendations and changes along the way to improve recruitment efforts. By having a successful recruitment campaign, you'll attain the ideal patients for your trial and have a higher chance of retainment. Once patients are enrolled and the trials begin, the...

- Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort - U.S. FDA 510(k) submission for Unyvero LRT BAL Application Cartridge in preparation Amsterdam,...

On Friday, Antisense Therapeutics Limited (ASX: ANP) announced that Phase II clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) is now fully enrolled. The trial is an open-label six-month dosage trial and is being carried out...

Alteogen Inc. (CEO Soon Jae Park), a South Korean biotechnology company developing Eylea biosimilar (ALT-L9) to treat macular degeneration, announced that it gained Investigational New Drug (IND) approval for Phase 1 clinical trial from Ministry of Food and Drug...

TROPHY1 data presented in Late-Breaking Trial Session at EuroPCR 2019 SoniVie, an Israeli company developing a novel system for the treatment of pulmonary arterial hypertension (PAH), today announced the presentation of positive data from a multi-center international...

The first patient has been dosed in a Phase 2B clinical trial evaluating the safety, efficacy, and tolerability of SAR442168 in people with relapsing multiple sclerosis(MS). SAR442168, formerly known as PRN2246, is being developed by Principia Biopharma, in...

Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled,...

- IMVT-1401, a fully human anti-FcRn antibody administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO - Immunovant plans to initiate ASCEND-GO 2, a separate Phase 2b dose-ranging clinical...

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced the receipt of the second milestone payment from Novartis following the initiation of a Phase 2 clinical...